Medical Services Department, Zuventus Healthcare Ltd, 5119 "D" Wing, Oberoi Garden Estate, Chandivilli, Mumbai 400072, India.
Gastroenterol Res Pract. 2011;2011:640685. doi: 10.1155/2011/640685. Epub 2011 May 5.
Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia. Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generation H(2)-RA, and rabeprazole and to compare their efficacy. Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of ≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafutidine 10 mg or rabeprazole 20 mg for 4 weeks. Results. A total of 236 patients were enrolled, out of which 194 patients were included in the analysis. At the end of week 4, a significant difference was observed for symptom relief (lafutidine 89.90% versus rabeprazole 65.26%, P < .01) and symptom resolution (lafutidine 70.71% versus rabeprazole 25.26%, P < .01). Both the drugs were well tolerated. Conclusion. Both lafutidine and rabeprazole provide symptom relief in patients with heartburn-dominant uninvestigated dyspepsia. The present study confirms the appropriateness of lafutidine as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.
长期以来，经验性治疗一直是未经调查的消化不良的传统方法，使用抗分泌药物如质子泵抑制剂（PPIs）和 H2 受体拮抗剂（H2RAs）。目的：本研究旨在考察拉呋替丁（第二代 H2RA）和雷贝拉唑对消化不良的缓解作用，并比较其疗效。方法：这是一项在未经调查的消化不良成年患者中进行的随机、开放、对照试验，患者至少有中度严重程度的症状，定义为 7 点总体症状（GOS）评分中的≥4 分，并随机接受每日一次拉呋替丁 10mg 或雷贝拉唑 20mg，治疗 4 周。结果：共纳入 236 例患者，其中 194 例患者纳入分析。在第 4 周末，症状缓解（拉呋替丁 89.90% vs 雷贝拉唑 65.26%，P <.01）和症状缓解（拉呋替丁 70.71% vs 雷贝拉唑 25.26%，P <.01）方面观察到显著差异。两种药物均耐受良好。结论：拉呋替丁和雷贝拉唑均可缓解烧心为主的未经调查的消化不良患者的症状。本研究证实拉呋替丁适用于经验性治疗，对消化不良患者的初级保健实践具有更好的疗效。
